News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cerulean Pharma Inc. (CERU) To Report Second Quarter 2014 Corporate Highlights And Financial Results On August 12, 2014



8/5/2014 8:03:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced that it will provide an update on corporate activities for the second quarter of 2014 on August 12, 2014.

Management will provide a business and financial update and outline future expectations via conference call at 4:30 p.m. ET on Tuesday, August 12, 2014. The conference call may be accessed by dialing 844.831.3031 for domestic participants and 443.637.1284 for international callers. The passcode for the call is 82082229.

A live audio webcast of the conference call will be available on the investors section of the Company's website: www.ceruleanrx.com. A replay of the conference call will be available approximately two hours after the event and will be available for two weeks following the conference call.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy. www.ceruleanrx.com

CONTACT: For IR: Heather Savelle MacDougall Biomedical Communications 781.235.3060 hsavelle@macbiocom.com For PR: Laura Kempke MSLGROUP 781.684.0770 cerulean@mslgroup.com

Cerulean logo

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES